Blue Trust Inc. Buys 7,157 Shares of Danaher Co. (NYSE:DHR)

Blue Trust Inc. boosted its holdings in Danaher Co. (NYSE:DHR) by 75.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,615 shares of the conglomerate’s stock after acquiring an additional 7,157 shares during the quarter. Blue Trust Inc.’s holdings in Danaher were worth $3,814,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in DHR. Coronation Fund Managers Ltd. lifted its position in Danaher by 29.9% in the 2nd quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock valued at $1,596,000 after acquiring an additional 1,470 shares in the last quarter. MidWestOne Financial Group Inc. increased its stake in Danaher by 12.9% in the 2nd quarter. MidWestOne Financial Group Inc. now owns 3,962 shares of the conglomerate’s stock valued at $990,000 after buying an additional 453 shares during the last quarter. Ascent Group LLC increased its stake in Danaher by 30.2% in the 2nd quarter. Ascent Group LLC now owns 2,205 shares of the conglomerate’s stock valued at $551,000 after buying an additional 512 shares during the last quarter. Aviso Wealth Management increased its stake in Danaher by 5.9% in the 2nd quarter. Aviso Wealth Management now owns 988 shares of the conglomerate’s stock valued at $247,000 after buying an additional 55 shares during the last quarter. Finally, Creative Planning increased its stake in Danaher by 6.0% in the 2nd quarter. Creative Planning now owns 122,591 shares of the conglomerate’s stock valued at $30,629,000 after buying an additional 6,969 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on DHR. Raymond James decreased their price objective on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Barclays decreased their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. KeyCorp raised their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Finally, Citigroup decreased their price target on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average price target of $285.55.

Danaher Stock Up 0.1 %

Shares of NYSE:DHR opened at $245.95 on Monday. The firm has a fifty day moving average price of $235.33 and a two-hundred day moving average price of $253.54. The company has a market cap of $177.65 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a one year low of $225.42 and a one year high of $281.70.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.